A Pennsylvania jury recently heard testimony that manufacturers of the popular blood thinner Xarelto botched the Xarelto bleeding warning that would have told patients about the serious risks.

A second trial regarding a Xarelto bleeding warning and the internal bleeding risks present for patients kicked off recently in Philadelphia as jurors heard arguments that Johnson & Johnson and Bayer knew about the dangerous internal bleeding risks but failed to tell doctors about the dangers posed when Xarelto is used with other drugs.

Jurors were told that combining Xarelto and anti-platelet medications significantly increased a patient’s risk of internal bleeding but the lack of a Xarelto bleeding warning meant that neither physicians nor patients were able to make an informed decision based on the warning label attached to the drug.

Anyone who has been seriously injured because of the lack of warning or other critical side effects may be eligible to participate in a lawsuit. Contact the attorneys at McDonald Worley for a free case review.

Xarelto Bleeding Lawsuit

According to the testimony provided regarding the lack of a Xarelto bleeding warning, this led to a serious gastrointestinal bleed suffered by one of the plaintiffs after taking a seven-day course of Xarelto treatment to cope with irregular heartbeat.

This is the fifth Xarelto bleeding warning trial facing Johnson & Johnson subsidiary Janssen Pharmaceuticals and Bayer Health Care Pharmaceuticals in federal and state courts. All of the lawsuits have a similar trend of being associated with severe internal bleeding risks linked with Xarelto.

Each of those trials ultimately went in favor of the two drug makers but a series of other trials are currently being held for those plaintiffs who allege that the manufacturers knew about the risks and failed to disclose it to the medical community and the public.

Plaintiffs intend to continue moving forward with these lawsuits to pursue claims that the drug makers didn’t properly warn about the risk of Xarelto bleeding when used in combination with Aspirin and Plavix. In combination with other drugs, a Xarelto bleeding warning may be much higher for a patient and these could lead to life-threatening events.

After the plaintiff in that Xarelto bleeding warning trial underwent emergency treatment in 2013 for an irregular heart beat and coronary artery, all of those medications were prescribed together.

The Plavix and Aspirin were prescribed to prevent clotting in the area following a stent being placed to the blocked artery. However, once the heart was shocked back into rhythm, the plaintiff received Xarelto to stop clots from forming in his heart.

The plaintiffs in these Xarelto lawsuits, however, say that the lack of an appropriate Xarelto bleeding warning label meant that they were not able to make an educated decision about what was in their best interests regarding using the medication in and of itself and in conjunction with other drugs.

Anyone who has been seriously injured because of the lack of warning or other critical side effects may be eligible to participate in a lawsuit. Contact the attorneys at McDonald Worley for a free case review.